Article
Signateraâ„¢ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
Neutral
0.0
−100 Bearish
0
+100 Bullish
AUSTIN, Texas, May 15, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
finance.yahoo.com
Published
May 15, 2026 · 12:45 pm
Article ID
7JXLNDF
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This